Original from: Revvity ¡¤ Revenue of $684 million; 2% reported growth; 2% organic growth ¡¤ GAAP EPS of $0.77; Adjusted EPS from continuing operations of $1.28 ¡¤ Raises full year 2024 adjust..

Original from: Illumina ¡¤ Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis ¡¤ Core Illumina GAAP operating margin of 68.6% and non-GAAP oper..

Sunbird Bio, a biotechnology company developing proprietary blood-based technologies to improve diagnosis and treatment of neurological disorders and early-stage cancer, announced new data demonstrating that the company¡¯s blood-biomarker alpha synuclein (¦Á-synuclein) signatures accurately detect the aggregation of ¦Á-synuclein in the brain from a simple blood draw. Results from the study, which will be shared in a poster presentation (#116) on October 31 at the Clinical Trials on Alzheimer¡¯s Disease (CTAD) international conference, demonstrate that Sunbird¡¯s technology could provide blood-based diagnosis of multiple neurodegenerative diseases, including Parkinson¡¯s disease, with high accuracy.

As part of ongoing efforts to enhance quality-assured testing options, the World Health Organization (WHO) has listed two additional mpox in vitro diagnostics under its Emergency Use Listing (EUL) procedure. WHO¡¯s EUL is based on the review of quality, safety and performance data in compliance with international standards while addressing the specific needs of low- and middle-income countries (LMICs).

Wolfe Research said Thursday that it has upgraded Danaher's shares to an Outperform rating from Peer Perform as the firm's growth is improving and it has capital to deploy.

Original from: Merck ¡¤ Total Worldwide Sales Were $16.7 Billion, an Increase of 4% From Third Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 7% - KEYTRUDA Sales Grew 17% to ..

Original from: bioM¨¦rieux ¡¤ +10.3% sales organic growth in the first nine months of the year with sales reaching €2,871m. A strong momentum fueled by the four growth drivers of the GO•28 strateg..

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024.

Original from: QIAGEN ¡¤ QIAstat-Dx Respiratory Panel Mini targets the five most actionable respiratory pathogens in outpatient settings to help clinicians make precise treatment decisions ¡¤ Wit..

The US Administration for Strategic Response and Preparedness' Biomedical Advanced Research and Development Authority (BARDA) announced Monday that it has awarded a $9.2 million contract to Revvity to develop a home-use test for the detection of SARS-CoV-2 and influenza A and B.

Eurofins Scientific (EUFI.PA), a global scientific leader in bioanalytical testing, with a rapidly developing presence in highly specialised and molecular clinical diagnostics testing and in-vitro diagnostic products, has reached an agreement with SYNLAB to acquire its clinical diagnostics operations in Spain. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025.

Devyser has achieved a significant regulatory milestone with its first market registration from China¡¯s National Medical Products Administration (NMPA) for Devyser Compact, an IVDR-certified genetic test for detecting fetal chromosomal abnormalities. Rapid prenatal aneuploidy detection kits fall under Class III IVD as part of the NMPA product registration process. This approval enables Devyser to market Devyser Compact as an in vitro diagnostic in China and paves the way for future regulatory approvals in the region for its simple, fast, and accurate genetic testing solutions.

Mindray Animal Technology Park Officially Breaks Ground in Shenzhen Mindray Animal Medical¡¯s global headquarters, also called Mindray Animal Technology Park, officially broke ground in Lon..

LabGenomics USA has successfully acquired Integrated Molecular Diagnostics (IMD) CLIA labs, bringing the total number of its CLIA-certified labs in the U.S. to four. This acquisition strengthens LabGenomics¡¯ strategic development and expands its diagnostic services nationwide, particularly in molecular technology.

Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the acquisition of EpiCapture Limited, a company developing a non-invasive test for monitoring the risk of aggressive prostate cancer. This acquisition marks Trinity Biotech¡¯s strategic expansion into the oncology diagnostics market.